Innovation Pharmaceuticals Inc (IPIX)

[loanranger]

At the time of the interim review, which was for safety, it was decided that the dosing regimen could be extended to 5 days from 3.
Even with the extended dosing period "Brilacidin did not show a difference compared to placebo in reducing Time to Sustained Recovery Through Day 29, the study’s primary endpoint based on clinical status".

I was referring to the efficacy as measured in the trial. Sorry if my language, though proper, confused you.